The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little geographical difference, US oncologists stressed more importance on the rate of disease progression compared to their EU based colleagues.
Oncologists also shared that information about efficacy is their most desired area for improvement by pharma. Information on side effects and use in expanded indications for earlier disease were preferred more by EU based physicians whilst US colleagues stressed greater importance on quality of life and real-world evidence.
About the study
The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM agile research solution. ONCpulseTM answers today’s business questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.
The objectives of the study were:
- Defining what ‘corporate leadership’ means to the oncology community
- Revealing the leaders (in oncology and IO) and an evaluation of their performance by oncologists
- Assessing current barriers and drivers to IO treatment choice and identifying oncologist views on areas for needed improvement by pharma.
Clients like you invest in MDOutlook as their partner of choice thanks to the positive accolade garnered from praise across the industry.
Want a report copy?
Sign up by clicking here.
If you would like a personalized leadership briefing and map out your teams future success, let’s take the next step to arrange a meeting using the Calendly link or by contacting us at [email protected] or via +1 404 496 4136.